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Abstract 
PDSS2 is a gene that encodes one of the two subunits of trans-prenyl diphosphate 
synthase that is essential for ubiquinone biosynthesis. It is known that mutations in 
PDSS2 can cause primary ubiquinone deficiency in human and a similar disease in 
mouse. Cerebellum is the most often affected organ in ubiquinone deficiency, and 
cerebellar atrophy has been diagnosed in many infants with this disease. In this study, 
two Pdss2 conditional knockout mouse lines directed by Pax2-cre and Pcp2-cre were 
generated to investigate the effect of ubiquinone deficiency on cerebellum during 
embryonic development and in adulthood, respectively. The Pdss2
f/-
; Pax2-cre mouse 
recapitulates some symptoms of ubiquinone deficiency in infants, including severe 
cerebellum hypoplasia and lipid accumulation in skeletal muscles at birth. During 
early cerebellum development (E12.5-14.5), Pdss2 knockout initially causes the delay 
of radial glial cell growth and neuron progenitor migration, so the growth of mutant 
cerebellum is retarded. During later development (E15.5-P0), increased ectopic 
apoptosis of neuroblasts and impaired cell proliferation result in the progression of 
cerebellum hypoplasia in the mutant. Thus, the mutant cerebellum contains fewer 
neurons at birth, and the cells are disorganized. The developmental defect of mutant 
cerebellum does not result from reduced Fgf8 expression before E12.5. Electron 
microscopy reveals mitochondrial defects and increased autophagic-like vacuolization 
that may arise in response to abnormal mitochondria in the mutant cerebellum. 
Nevertheless, the mutant mice die soon after birth probably due to cleft palate and 
micrognathia, which may result from Pdss2 knockout caused by ectopic Pax2-cre 
expression in the first branchial arch. On the other hand, the Pdss2
f/-
; Pcp2-cre mouse 
is healthy at birth but gradually loses cerebellar Purkinje cells and develops 
ataxia-like symptoms at 9.5 months; thus this conditional knockout mouse may serve 
as a model for ubiquinone deficiency in adult patients. In conclusion, this study 
provides two mouse models of Pdss2 based ubiquinone deficiency. During cerebellum 
development, Pdss2 knockout results in severe cerebellum hypoplasia by impairing 
cell migration and eliciting ectopic apoptosis, whereas Pdss2 knockout in Purkinje 
cells at postnatal stages leads to the development of cerebellar ataxia. 
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Introduction 
 Ubiquinone (coenzyme Q) is an important lipid soluble electron carrier in the 
mitochondrial respiratory chain, in which it transports electrons from Complex I or 
Complex II to Complex III. As a well-known antioxidant, ubiquinone prevents cells 
from reactive oxygen species (ROS) damage by scavenging free radicals. Besides, it 
is also involved in the modulation of thermogenesis and mitochondrial permeability 
transition (MPT) (Klingenberg and Echtay, 2001; Walter et al., 2000). Primary 
ubiquinone deficiency is a rare heterogeneous genetic disorder in human. There are 
five subtypes of ubiquinone deficiency according to different clinical symptoms, and 
skeletal muscle, cerebellum, and kidney are often affected (Quinzii et al., 2007a; 
Quinzii et al., 2007b). Although this disease is usually treated by prolonged CoQ10 
therapy, not all patients demonstrate substantial improvement, especially for those 
who have already developed severe lesions in central nerve system (CNS) or kidney 
(Rotig et al., 2000; Salviati et al., 2005). 
 Mammals can acquire ubiquinone either from diet or by de novo synthesis. 
However, since the intestinal ubiquinone uptake is usually inefficient, human body 
largely relies on endogenous ubiquinone under normal circumstance (Turunen et al., 
2004). Consequently, any genetic defect in ubiquinone biosynthesis or metabolism 
will result in primary ubiquinone deficiency. Ubiquinone is composed of a modified 
quinonoid ring derived from para-hydroxybenzoate (PHB) and a polyprenyl side 
chain with varied numbers of isoprene subunits. In animals, PHB is derived from 
tyrosine or phenylalanine, and isoprene is synthesized from acetyl CoA through 
mevalonate pathway (Meganathan, 2001; Quinzii et al., 2007b). The long isoprenyl 
side chain is essential to maintain the molecule’s hydrophobicity, which enables 
ubiquinone to perform important biological functions in various cell membranes. One 
crucial enzyme for the condensation of polyprenyl side chain is trans-prenyl 
diphosphate synthase (PDS), which also determines the predominant side chain length 
of ubiquinone in a given species (Turunen et al., 2004). In human and mouse, PDS is 
a heterotetramer consisting of two PDSS1 subunits and two PDSS2 subunits, and both 
of them are indespensible for PDS enzymatic activity (Saiki et al., 2005). 
As PDS is the enzyme at the first committed step in ubiquinone synthesis, 
mutations in either PDSS1 or PDSS2 gene can result in primary ubiquinone deficiency 
in human (Lopez et al., 2006; Mollet et al., 2007). Interestingly, a mouse strain (kd/kd) 
harboring a spontaneous mis-sense mutation in Pdss2 gene also develops a 
progressive kidney disease similar to that observed in ubiquinone deficient patients 
with defective PDSS2 gene (Peng et al., 2008). At about 8 weeks old, the kd/kd mouse 
develops kidney symptoms reminiscent of human juvenile collapsing glomerulopathy, 
and it gradually progresses to end stage renal disease at 16-40 weeks (Peng et al., 
2004). Further characterization of this mutant mouse has revealed that kidney 
podocytes, which are selectively affected, undergo de-differentiation and overlay the 
collapsed capillary loops (Barisoni et al., 2005). Moreover, CoQ10 supplementation 
can also alleviate the renal symptoms of kd/kd mouse to some extent (Saiki et al., 
2008). Thus, this mutant mouse can be utilized to study the kideny symptoms of 
human ubiquinone deficiency, but other organs commonly involved in the disease are 
not affected. Therefore, a more sophisticated tissue specific Pdss2 knockout mouse 
model will be valuable to elucidate the pathogenesis of ubiquinone deficiency in 
different organs. 
The mouse homologous gene of human PDSS2, Pdss2, is located on chromosome 
10 (10q B2). Both mouse Pdss2 and human PDSS2 contain eight exons, and there are 
at least two mRNA variants arising from alternative splicing, but it is believed that the 
longer form including all eight exons is fully functional (Lopez et al., 2006; Saiki et 
al., 2005). Human and mouse PDSS2 proteins are also very similar in that they both 
consist of seven conserved domains. In the kd/kd mutant mouse, the renal disease is 
considered to be associated with a point mutation in exon 2 of Pdss2, which leads to 
an amino acid substitution (V117M) in the first conserved domain (Peng et al., 2004; 
Saiki et al., 2005), suggesting the important function of this region in PDSS2 protein. 
Previously, we generated a Pdss2 floxed mouse (Pdss2
f/f
) with exon 2 flanked by two 
LoxP sites. However, with the deletion of Pdss2 exon 2, the total knockout mouse 
(Pdss2
-/-
) is embryonic lethal, which is consistent with the hypothesis that ubiquinone 
is essential for mouse embryonic development (Levavasseur et al., 2001). 
Consequently, a tissue specific knockout strategy has to be adopted. 
Tissue specificity is a prominent feature of ubiquinone deficency. In addition to 
kidney, cerebellum is one of the most often affected organs in ubiquinone deficiency, 
as it is involved in four out of five subtypes of this disease (Rotig et al., 2007). 
Meanwhile, a considerable portion of genetically undefined cerebellar ataxia is 
associated with ubiquinone deficiency (Lamperti et al., 2003). Because of its limited 
capacity of repair, cerebellum is more vulnerable than skeletal muscles, as patients 
with cerebellar atrophy cannot fully recover after CoQ10 therapy (Lalani et al., 2005; 
Ogasahara et al., 1989). Furthermore, in some cases of ubiquinone deficiency, 
cerebellar atrophy may develop very early in life, even at infantile stage (Lopez et al., 
2006; Musumeci et al., 2001). Thus, it is possible that cerebellum has already been 
affected during embryonic development. However, the pathogenesis of cerebellum 
defect in ubiquinone deficient patients has not been thoroughly investigated due to 
limited clinical samples, and there has not been any mouse model established so far to 
address this issue. Therefore, the main objective of this study is to analyze the 
cerebellum defect in ubiquinone deficiency with the emphasis on cerebellum 
development using a Pdss2 conditional knockout mouse model. In order to achieve 
Pdss2 knockout in developing cerebellum, the previously generated Pdss2 floxed 
mouse (Pdss2
f/f
) was crossed with a Pax2-cre deleter mouse, in which Cre 
recombinase is expressed in the hindbrain region at E9.5 and influences many cells in 
cerebellum at birth (Ohyama and Groves, 2004). At the same time, a more specific 
deleter mouse Pcp2-cre (Zhang et al., 2004) was also crossed with Pdss2
f/f
 mouse to 
generate another tissue specific knockout mouse (Pdss2
f/-
; Pcp2-cre), where Pdss2 
knockout occurs only in cerebellum Purkinje cells after birth. This latter conditional 
knockout mouse can be used to study the cerebellar defects of ubiquinone deficiency 
in adulthood. 
 In this study, two Pdss2 conditional knockout mice (Pdss2
f/-
; Pax2-cre and 
Pdss2
f/-
; Pcp2-cre) were generated. The phenotypes of Pdss2
f/-
; Pax2-cre mouse were 
characterized at birth with respect to human ubiquinone deficiency, and the 
cerebellum development was also studied at different embryonic stages. Besides, the 
cerebellum of Pdss2
f/-
; Pcp2-cre mouse was briefly studied at different ages in 
adulthood. 
Materials and methods 
Mouse breeding and colony maintenance 
 All mice used in this study were maintained on a common C57BL/6N (C57) 
genetic background at the minimum disease area of the Laboratory Animal Unit in the 
University of Hong Kong, and the experimental protocols were approved by the 
Committee on the Use of Live Animals in Teaching and Research (CULATR). Mice 
were marked by ear puncture, and DNA was extracted from ear clips as described 
before (Wu et al., 2008). Mouse genomic DNA (50-100 ng) was used as template for 
one routine PCR genotyping. The genotyping primers and amplification conditions 
are summarized in Table 1, and typical results shown in Fig. 1A. For timed mating, 
the day when vaginal copulation plug was observed was considered as E0.5, and the 
desired embryonic stage was counted accordingly. 
The breeding strategy to generate tissue specific knockout mouse from the 
founder is illustrated in Supplementary data (Fig. S3), and different Pdss2 alleles 
involved are demonstrated in Fig. 1A. Briefly, the founder mouse (Pdss2
f-E-Neo/+
) was 
crossed to β-actin-cre (Lewandoski et al., 1997) for heterozygous knockout mouse 
(Pdss2
+/-
) and to FLPeR (Farley et al., 2000) for heterozygous floxed mouse 
(Pdss2
f/+
). Then, Pdss2
+/-
 mouse was bred with tissue specific deleter mouse Pax2-cre 
(Ohyama and Groves, 2004) or Pcp2-cre (Zhang et al., 2004) to produce the 
compound mutant mouse Pdss2
+/-
; Pax2-cre or Pdss2+/-; Pcp2-cre. Meanwhile, the 
homozygous floxed mouse (Pdss2
f/f
) was obtained by intercrossing Pdss2
f/+
 mice. In 
order to demonstrate the Pax2-cre and Pcp2-cre expression pattern, ROSA26
lacZ
 
reporter gene was introduced by crossing Pdss2
f/f 
mouse with ROSA26
laZ/lacZ
 mouse 
(Soriano, 1999). Finally, Pdss2
+/-
; Pax2-cre or Pdss2
+/-
; Pcp2-cre male mice were 
crossed to either Pdss2
f/f
 or Pdss2
f/f
; ROSA26
laZ/lacZ
 female mice from the same 
generation to produce desired tissue specific knockout mice (Pdss2
f/-
; Pax2-cre or 
Pdss2
f/-
; ROSA26
laZ/+
; Pax2-cre and Pdss2
f/-
; Pcp2-cre or Pdss2
f/-
; ROSA26
laZ/+
; 
Pcp2-cre). In most experiments, progenies from the same dame were used. 
RNA extraction and RT-PCR 
 Total RNA was extracted from mouse kidney using Trizol reagent (Invitrogen) 
following the manufacturer’s instruction. Reverse transcription was performed using 
1-3 μg total RNA as template with Moloney Murine Leukemia Virus (M-MLV) 
reverse transcriptase (Promega) according to the instruction. Subsequently, the 
fragment of Pdss2 exon 1 to part of exon 5 was amplified from cDNA by RT-f1 
(5’-ATGAGCCTCCGGCAGCTGCTG-3’) & RT-r5 (5’- 
CTGGCAGCTCTTCGCTAGCA-3’). The desired PCR products were purified and 
sequenced using Pdss2-Ex3-seq-r1 (5’-AGAAAGTCTCCACTCAGGATAGCT-3’). 
Western blot 
 Protein from freshly isolated mouse tissue was extracted with 50-200 μL RIPA 
buffer (50 mM Tris·HCl (pH7.5), 150 mM NaCl, 0.5% sodium dexoycholate, 1% 
NP-40) supplemented with 0.05 mM PMSF and complete protease inhibitor cocktail 
(Roche). For each sample, 10-20 μg protein was resolved by 12% SDS-PAGE and 
transferred to a PVDF membrane (Hybond
TM
-C super membrane, Amersham 
Bioscience). The membrane was blotted with a mouse monoclonal antibody against 
PDSS2 (1:2,000, Wolwo Biotech) (Fung et al., 2009) and a mouse monoclonal 
antibody against α-tubulin (1:10,000, Sigma). The size of PDSS2 and α-tubulin was 
detected as 37 KDa and 55 KDa, respectively. 
Whole mount in situ hybridization and histochemistry 
 Embryos at E10.5 and E11.5 were collected for whole mount in situ hybridization 
following the protocol described previously (Wilkinson, 1992) with modifications 
described below. The embryos were treated by 10 μg/mL proteinase K (Roche) in 
PBST at RT: 50 min for E10.5 and 90 min for E11.5. For final color development, the 
embryo was incubated with BM purple solution (Roche) at RT until satisfactory color 
achieved. The plasmid of Fgf8 probe was generously provided by Prof. K. SE. Cheah 
(Crossley and Martin, 1995). It was linearized with BamH I and used as template to 
synthesize a DIG labeled RNA probe (about 850 bp) by in vitro transcription (DIG 
RNA labeling kit, Roche). The final concentration of labeled probe was 0.1-0.2 ng/μL 
for whole mount in situ hybridization. 
 Whole mount skeleton staining with Alcian blue & Alizarin red S was performed 
according to the procedure described before (Kimmel and Trammell, 1981; McLeod, 
1980). Whole mount X-gal staining was conducted as described previously (Zhang et 
al., 2004). Embryos younger than E12.5 were directly stained. For older embryos and 
postnatal mice, tissues of interest were first isolated and then stained separately. 
Histology and immunohistochemistry 
 For routine paraffin section, mouse tissues or embryos were fixed in 10% neutral 
buffered formalin at 4℃ overnight and dehydrated through ethanol series. The tissues 
were embedded with proper orientation in paraffin and sectioned at 5-7 μm thickness 
(Microm-HM340E, Leica). For frozen section, tissues were fixed in 10% neutral 
buffered formalin at 4℃ for 3-4 hr and infiltrated with 30% sucrose (in PBS) at 4℃ 
overnight. Tissues were embedded with OCT compound (Leica Microsystems) and 
frozen in isopentane cooled by liquid nitrogen. Then the tissue blocks were archived 
at -80℃ and sectioned at 7-10 μm (CM 1900UV, Leica). Routine H&E staining and 
Sudan black staining for lipid were performed following the protocols described 
previously (Carson, 1990). 
 For immunostaining, the primary antibodies were applied as followed: mouse 
anti-CALB-28K (Sigma) at 1:100, rabbit anti-β-galactosidase (Cappel-INC, MP 
Biomedicals) at 1:400, mouse anti-nestin (BD Pharmigen) at 1:2,000, and mouse 
anti-TUJ1 (Convance) at 1:500. HRP conjugated goat anti-rabbit or anti-mouse IgG 
antibody (Dako cytomation, Envision + system) was used for immunohistochemistry, 
and color was developed by DAB (Dako). For immunofluorescence, Cy3 labeled goat 
anti-rabbit IgG (1:5,000, Jackson ImmunoResearch Laboratories) was applied, and 
section was mounted with anti-fade reagent containing DAPI (Invitrogene). 
Cell proliferation and apoptosis assay 
 Cell proliferation in mouse embryo was studied by BrdU incorporation assay. 
BrdU stock solution (5 mg/mL, Sigma) was administered to pregnant mice via 
intra-peritoneal injection (50 μg BrdU per gram body weight) 2 hr prior to 
euthanization. The embryos were processed for paraffin section as usual. Brain 
sections were pre-treated with trypsin at 37℃ for 5-7 min, and BrdU detection was 
performed using BrdU staining kit (Zymed, Invitrogen) according to the instruction. 
 Apoptosis was examined by TUNEL assay using in situ cell death detection kit 
(Roche) with the following modifications. Paraffin sections of newborn mouse brain 
or embryos were pre-treated with permeabilizing solution (0.1% Triton X-100, 0.1% 
sodium citrate) for 7 min at RT, whereas adult mouse brain samples were digested by 
25 μg/mL proteinase K (Roche) for 30 min at 37℃. For immunohistochemistry, the 
concentration of convertor-POD solution was reduced to 1/3 (diluted with TBS) to 
lessen the background. 
Electron microscopy 
 Cerebellum was retrieved from adult mice or embryos and cut into small blocks. 
They were fixed with 2.5% glutaraldehyde (in 0.1 M cacodylate buffer) at 4℃for 4 hr, 
washed, and infiltrated with 0.1 M sucrose at 4℃ overnight. After three washes with 
0.1 M cacodylate buffer, the tissues were post-fixed in 1% OsO4 at RT for 1 hr. Then, 
the tissues were dehydrated through ethanol series, infiltrated with epoxy resin, and 
embedded at proper orientation. Sections were cut by ultramicrotom (Leica Ultracut 
UCT) and examined by transmission electron microscope (Philips EM208s) at the 
Electron Microscope Unit of the University of Hong Kong. 
Foot print assay 
 Four mutant (Pdss2
f/-
; Pcp2-cre) mice and their control littermates (Pdss2
f/+
; 
Pcp2-cre) were evaluated by foot printing assay following the same method as 
described previously (Gerfen et al., 2007). Results from 5 days (at least 3 repetitive 
walking tasks for each mouse on each day) were analyzed. The stride length between 
two consecutive steps was measured on both left and right side manually. An 
additional step is recognized when a footprint of forepaw has no matching footprint of 
hindpaw or vice versa. A walking task is considered to have additional steps if at least 
one additional step (on either left or right side) is recognized during the distance used 
for calculating stride length. The frequency of walking tasks with additional steps for 
an individual mouse is calculated as (the number of walking tasks with additional 
steps / total number of walking tasks examined) x 100%. 
Statistical analysis 
 For Pdss2 conditional knockout mice driven by Pax2-cre, embryos with the same 
genotype at a given stage were pooled. In BrdU assay, the overall cell density (total 
cell count / area in μm2) and BrdU index (the number of BrdU positive cells / total 
cell number) were calculated. In TUNEL assay, the percentage of apoptotic cells is 
calculated (the number of apoptotic cells / total cell count). For every embryo, two 
adjacent coronal sections through cerebellum were examined by counting all 
recognizable cells in the cerebellum, and the average was taken. Specifically, the 
average total cell count was 5,000 for control and 4,000 for mutant at E12.5, and 
10,000 for control and 5,500 for mutant at E14.5. Cell counting and area measurement 
were performed using Image J (Ver. 1.43, NIH). Data from 3-4 control or mutant 
embryos at each stage were used for statistics. Cerebellum coronal sections at E18.5 
were also studied by electron microscopy: 4 randomly selected areas (at least 30 cells 
per area) on each section were examined. Cells with both abnormal mitochondria and 
strong lysosomal activity (reflected by residual bodies and autophagic-like vacuoles) 
were considered showing autophagic-like features. The percentage of those 
autophagic-like (potential or putative autophagic) cells in total cell count of each 
randomly picked area was calculated. For statistical analysis, independent t-test was 
performed with SPSS (Ver. 17.0). 
 For foot print assay of Pdss2 conditional knockout mice driven by Pcp2-cre, the 
mean stride length was calculated for the left and right side separately. Full factorial 
ANOVA was performed considering the main effect of side, litter, and genotype. The 
percentage of walking with additional steps was subjected to ANOVA considering the 
main effect of litter and genotype.  
(Table 1) 
Results 
Generation of Pdss2 conditional knockout mouse 
Detailed procedures of targeting vector construction, ES cell selection, and 
founder mouse (Pdss2
f-E-Neo/+
) verification are described in Supplementary data (Fig. 
S1-S2). Those confirmed founders were used in subsequent breeding to generate 
homozygous floxed mice (Pdss2
f/f
) and heterozygous knockout mice with Pax2-cre 
transgenic background (Pdss2
+/-
; Pax2-cre). By crossing these two mice (Pdss2
+/-
; 
Pax2-cre X Pdss2
f/f
), tissue specific knockout mice (Pdss2
f/-
; Pax2-cre) were obtained 
at a theoretical ratio of 1/4. Another tissue specific knockout mouse line (Pdss2
f/-
; 
Pcp2-cre) was generated in a similar way by replacing Pax2-cre mouse with Pcp2-cre 
mouse. This breeding strategy is described in Materials and methods and illustrated in 
Fig. S3. The structures of different Pdss2 alleles and typical genotyping results are 
demonstrated in Fig. 1A. 
The homozygous total knockout mouse (Pdss2
-/-
) is embryonic lethal. The oldest 
Pdss2
-/-
 embryo identified is at E9.5, and its morphology resembles normal E6.5 
mouse embryo (data not shown), so the development of mutant embryo may be 
blocked at late gastrula stage due to Pdss2 knockout. The deletion of Pdss2 exon 2 in 
heterozygous knockout mice (Pdss2
+/-
) was further confirmed by RT-PCR and 
sequencing (Fig. 1B, Fig. S4). At birth, the PDSS2 protein level in various tissues of 
Pdss2
f/-
; Pax2-cre mice was compared with that of litter mate controls (Pdss2
f/-
 and 
Pdss2
f/+
) by Western blot (Fig. 1C). Since Pdss2 knockout is driven by Cre 
recombinase in the conditional knockout mouse (Pdss2
f/-
; Pax2-cre), it demonstrates a 
spatial and temporal pattern similar to that of endogenous Pax2 expression. It has 
been shown that Pax2-cre is mainly expressed in the midbrain-hindbrain region 
during embryonic development and also in kidney at birth (Ohyama and Groves, 
2004). In consistent with this pattern, PDSS2 protein is reduced in kidney of Pdss2
f/-
; 
Pax2-cre mice. Midbrain and pons also demonstrate some degree of PDSS2 decrease, 
whereas medulla is less affected. More importantly, PDSS2 is almost depleted in the 
cerebellum of mutant mice, indicating Pdss2 knockout in cerebellum is successful. 
Interestingly, PDSS2 protein also decreases in the forelimb muscle, and this may 
result from the ectopic Pax2-cre expression in limb buds during early development 
(Fig. 2C). 
(Fig. 1) 
Neonatal death and skeletal muscle defect of Pdss2
f/-
; Pax2-cre mouse 
 Although the tissue specific knockout mice (Pdss2
f/-
; Pax2-cre) can be born alive, 
they invariably die within the first 36 hr of life. About 50% of them (21 out of 42 
mutant mice examined at birth) are identified with cleft palate, which is a common 
cause of neonatal death in transgenic mice. Cleft palate causes the incomplete 
separation of oral and nasal cavity, leading to dysphagia and respiratory distress. As 
demonstrated in Fig. 2A, the most anterior pre-maxilla of the mutant mouse still 
develops normally, but the two palatine shelves of definitive palate retain a vertical 
position and fail to fuse along the midline. Therefore, the development of palate may 
be blocked around E12.5-13.5 in those mutant mice. On the other hand, even though 
the mutant mice with normal palate survive longer, they eventually die of starvation, 
since no milk was found in the stomach. Notably, all mutant mice including those 
with cleft palate exhibit micrognathia to some extent. Micrognathia is characterized 
by the under-development of mandible, which is often associated with cleft palate 
causing respiratory distress and dysphagia in infants. As shown in Fig. 2B, mandible 
is normally aligned with maxilla in control mice, whereas it becomes much shorter 
than maxilla in mutant mice. Such mis-alignment of mandible with maxilla impairs 
feeding, and the posterior displacement of mandible may also result in glossoptosis, 
leading to pharynx compression and upper airway obstruction. Thus, micrognathia is 
generally related to the neonatal death of all mutant mice, and cleft palate may further 
accelerate the death of some mutants. 
 Since both maxilla and mandible are derived from the first branchial arch (BA1) 
during development, Pax2-cre expression in this region was studied by X-gal staining 
(Fig. 2C). At E10.5, in addition to midbrain and hindbrain, β-galactosidase activity is 
also detectable in BA1, and this ectopic Cre expression may result from some neural 
crest cells migrating from the corresponding hindbrain region where Pax2-cre has 
been expressed. Thus, Pdss2 knockout may also take place in the cells of BA1, 
affecting the development of maxilla and mandible in mutant mice. Besides, limb 
buds also demonstrate Pax2-cre expression at E10.5 for unknown reason, and PDSS2 
protein is also reduced in forelimb muscle of mutant mice at birth (Fig. 1D). In 
consistent with reduced PDSS2 protein level, lipid accumulation is evident in the 
forelimb skeletal muscle of mutant mice at P0 (Fig. 2D). Such abnormal lipid 
accumulation in skeletal muscles is also a common symptom of ubiquinone 
deficiency in human. 
(Fig. 2) 
Cerebellum hypoplasia and disorganized cell arrangement around birth 
 Cerebellum hypoplasia is a common feature of all tissue specific knockout mice 
(Pdss2
f/-
; Pax2-cre) around the time of birth. As demonstrated by whole brain X-gal 
staining at E17.5 (Fig. 3E-G), the size of both midbrain and cerebellum is severely 
reduced in mutant mice. Specifically, hypoplasia is more severe at the vermis (midline 
region) than in cerebellar hemispheres. Furthermore, coronal sections of X-gal stained 
brain also reveal that most cells in the cerebellum are affected by Pax2-cre at E17.5 
(Fig. 3H-I’), which is consistent with the loss of PDSS2 protein in mutant cerebellum 
at P0 (Fig. 1D). Thus, the cerebellum hypoplasia observed in Pdss2
f/-
; Pax2-cre 
mouse around birth recapitulates cerebellar atrophy present in some infants with 
severe ubiquinone deficiency. 
At P0, the mutant cerebellum fails to develop normal surface foliations (Fig. 3A1, 
3B1), and it contains fewer cells compared with the control cerebellum, especially in 
the vermis region (Fig. 3A2, 3B2). In addition, the cell stratification is also 
disorganized. In the normal cerebellum, Purkinje cells have already formed a layer 
beneath the outmost external granule cell layer (Fig. 3A1), and they can be identified 
as parallel clusters by the expression of Purkinje cell marker, CALB-28K (Fig. 3C, 
3C’). However, this layer is absent in the mutant cerebellum (Fig. 3B1), and the 
expression of CALB-28K is not clearly evident (Fig. 3D). This may imply a failure in 
Purkinje cell maturation or loss of neural progenitors during cerebellum development. 
Moreover, in contrast to the control cerebellum, in which neurons are evenly 
distributed and form well defined clusters, most cells in the mutant cerebellum are 
highly compacted close to the ventricular surface, leaving the dorsal region devoid of 
cells (Fig. 3A1, 3B1). This disorganization of cell arrangement may represent a defect 
in the upward migration of neural progenitors from ventricular zone at earlier stages. 
Therefore, in addition to the overall decrease in cerebellum size, the normal cellular 
organization is also disrupted in the mutant cerebellum. 
(Fig. 3) 
The initiation of cerebellum growth retardation during E12.5-14.5 due to defects in 
radial cell migration 
 Until E12.5, there is no apparent morphological difference between the control 
and mutant cerebellum, neither ectopic apoptosis nor reduced cell proliferation is 
detected (data not shown). However, the growth of mutant cerebellum becomes 
severely retarded since E12.5. During E12.5-14.5, the control cerebellum has 
dramatic changes in size and shape (Fig. 4A, C). In contrast, the mutant cerebellum 
fails to expand during this period and retains a similar shape as before, so it appears to 
be much smaller than the control cerebellum at E14.5 (Fig. 4B, D). 
 In order to account for this growth retardation, cell proliferation was first 
compared between control and mutant cerebellum at E12.5 and E14.5 using BrdU 
assay (Fig. 4E-H). As expected, the proliferating (BrdU positive) cells are 
concentrated at the sub-ventricular zone in both control and mutant cerebellum, and 
the percentage of proliferating cells decreases during E12.5-14.5 (Fig. 4N). Based on 
BrdU index calculation, there is no significant difference in cell proliferation between 
control and mutant at both stages (Fig. 4N). However, further analysis of cerebellum 
cell density change during E12.5-14.5 reveals that the cerebellum growth is not only 
the result of cell proliferation but also depends on the expansion of cerebellum 
volume. As shown in Fig. 4M, the overall cell density of control cerebellum has 
decreased by about 50% from E12.5 to E14.5. On the contrary, although the mutant 
cerebellum has a similar cell density as control at E12.5, it shows a significantly 
higher overall cell density compared to control at E14.5, indicating a failure in 
cerebellum expansion during this period. This difference of overall cell density is also 
evident in the coronal section of control and mutant cerebellum at E14.5 (Fig. 4C-D). 
 In normal cerebellum, as neuron progenitors migrate upwards from the 
ventricular zone to the marginal zone, the above intermediate zone containing more 
differentiated cells is increasing in thickness during E12.5-14.5. Radial cell migration 
and intermediate zone expansion contribute to the rapid growth of cerebellum, and the 
overall cell density also decreases during this process because the emerging 
intermediate zone has a much lower cell density. Therefore, the growth retardation of 
mutant cerebellum may result from defects in radial cell migration. In fact, the cell 
arrangement has already become different between control and mutant since E12.5. In 
control cerebellum, cells above the proliferating sub-ventricular zone are arranged 
into parallel columns and demonstrate an obvious trend of radial migration (Fig. 4E). 
On the contrary, there are fewer cells above the proliferating cell layer, and their 
arrangement is completely disordered in mutant cerebellum (Fig. 4F). Therefore, at 
E12.5, neuron progenitors in control cerebellum may leave the proliferating status and 
start radial migration, whereas this process does not commence in the mutant. Radial 
glial cells play an important role in neuron progenitor migration because they function 
as scaffolds for the migrating cells. Therefore, the presence of radial cells was 
examined by staining for their cell marker, nestin. At E12.5, radial glial cells grow 
from the ventricular zone and project their process towards the marginal zone, 
representing the route of radial cell migration in control cerebellum (Fig. 4I, 4I’). 
Instead, there is only limited amount of radial glial cells in mutant cerebellum at 
E12.5, and the processes of these cells are much shorter (Fig. 4J, 4J’). Therefore, 
defects in radial cell growth compromise the radial cell migration, and this may 
contribute to the growth retardation of mutant cerebellum. Furthermore, as neuron 
progenitors migrate into the intermediate zone, they start to maturate and express 
neuron specific markers, such as Tuj1. In the mutant cerebellum, since most neuron 
progenitors are retained in the sub-ventricular zone, their maturation is also delayed. 
From Fig. 4K-L, there are more Tuj1 negative cells confined to the sub-ventricular 
zone even at E14.5, indicating a delay in the expansion of intermediate zone in mutant 
cerebellum. 
(Fig. 4) 
Increased ectopic apoptosis companies the progression of cerebellum hypoplasia 
since E14.5 
Although the growth of mutant cerebellum has already become retarded during 
E12.5-14.5, ectopic apoptosis has not become significant until E14.5, as demonstrated 
by the percentage of apoptotic cells (Fig. 5A-C). Such ectopic apoptosis becomes 
more obvious at E15.5 and increases continuously until E18.5. Most apoptotic cells 
appear as clusters in the intermediate zone of mutant cerebellum (Fig. 5E’, G’). 
Furthermore, with the aid of ROSA26
lacZ
 reporter, immunostaining of β-galactosidase 
demonstrates that apoptosis is co-localized with the region where Cre has been 
expressed in mutant cerebellum (Fig. 5K’). In addition to ectopic apoptosis, 
neuroblast proliferation is also reduced in mutant cerebellum, and these neuroblasts 
are also affected by Pax2-cre, as revealed by X-gal staining (Fig. 5H-I’).  
Therefore, the increased ectopic apoptosis since E14.5 further aggravates the 
growth retardation initiated at earlier developmental stages (E12.5-14.5) and 
eventually leads to severe cerebellum hypoplasia in the mutant mouse. At birth, the 
mutant cerebellum contains fewer cells due to neuron loss by intensive apoptosis 
during E14.5-P0. In addition, the normal cellular organization is not established, as 
most cells are compacted close to the ventricular zone. Such morphological defects 
may reflect the impairment of radial cell migration during E12.5-14.5. Moreover, as 
the major cause of neuron loss, apoptosis is co-localized with Pax2-cre expression, so 
Pdss2 knockout is likely to cause neuron loss in the mutant cerebellum. 
(Fig. 5) 
Normal Fgf8 expression in the isthmus of mutant embryo before E11.5 
 Fibroblast growth factor 8 (FGF8) released by isthmus during E9.5-12.5 
promotes cell survival and differentiation in cerebellum. Considering that the 
development of radial glial cell is affected in Pdss2
f/-
; Pax2-cre embryos at E12.5, and 
Pax2 plays an important role in Fgf8 expression, Pdss2 knockout may impair 
cerebellum development indirectly via reduced FGF8 production. Nevertheless, in 
situ hybridization shows that normal Fgf8 expression at isthmus is maintained in the 
mutant embryo until E11.5 (Fig. 6). Thus, the development defect observed at E12.5 
and afterwards is not caused by reduced FGF8 level at earlier stages. 
(Fig. 6) 
Abnormal mitochondria and autophagic-like structures in the cells of mutant 
cerebellum 
 The sub-cellular morphology of mutant cerebellum was studied by transmission 
electron microscope (TEM) at E18.5. In consistent with TUNEL assay, massive 
apoptotic cells are also evident in the mutant cerebellum (Fig. 7C). The mitochondria 
in control cerebellum cells possess smooth membrane with regular cristae, and the 
matrix is homogeneous and electron-dense (Fig. 7B). In contrast, abnormal 
mitochondria are found to accumulate in those surviving cells of mutant cerebellum: 
they are swollen and devoid of cristae, and the mitochondrial matrix becomes pale 
and loses electron density (Fig. 7D). Interestingly, in many of those cells that still 
survive, defective mitochondria are engulfed by rER (Fig. 7E), and elevated 
lysosomal activity is also evident by increased residual bodies (Fig. 7F-G). These 
morphological features imply that autophagy of abnormal mitochondria may be 
involved, and the percentage of cells with such autophagic-like structures has 
significantly increased in the mutant cerebellum (Fig. 7H). Consequently, 
mitochondrial defect may trigger the apoptosis, whereas autophagic-like vacuoles 
may also arise to remove abnormal mitochondria and promote cell survival in the 
mutant cerebellum. 
(Fig. 7) 
Gradual development of ataxia in Pdss2
f/-
; Pcp2-cre mouse 
 Since the neonatal death of Pdss2
f/-
; Pax2-cre mouse precludes further study at 
adult stage, a more specific deleter mouse strain, Pcp2-cre, was used to produce 
another Pdss2 conditional knockout mouse (Pdss2
f/-
; Pcp2-cre or Pdss2
f/-
; 
ROSA26
lacZ/+
; Pcp2-cre). In Pcp2-cre mouse, Cre recombinase is expressed only in 
cerebellar Purkinje cells and retinal bipolar neurons, and the expression starts at day 7 
after birth (P7) and reaches its peak level at P15 (Zhang et al., 2004). Thus, this 
Pcp2-cre mouse allows further anaylsis of Pdss2 function in cerebellum at postnatal 
stages. The mutant mice (Pdss2
f/-
; Pcp2-cre) remain healthy and do not show any 
abnormal behavior at 4.5 months (Video 1-2). Nevertheless, failure in motor 
coordination during walking and incapability of maintaining balance on a rod have 
been observed at 9.5 months (Video 3-4). This phenotype resembles ataxia in human 
ubiquinone deficiency, and it becomes more severe in elder mutant mice. At 1 year 
old, the ambulation of mutant mice was assessed by footprinting assay, and the results 
were compared with their control litter mates (Fig. 8). The steps of control mice are 
evenly spaced, and the forepaw tends to overlap well with the hindpaw on the same 
side (Fig. 8A). In contrast, the stride length of mutant mice is shorter and more 
variable, and additional steps made by both forepaw and hindpaw are more frequent 
than control over the same walking distance (Fig. 8B). Even though the mutant mice 
take more steps in order to compensate motor incoordination, they sometimes still fail 
to maintain balance and slip to one side (Fig. 8C). Similarly, statistical analysis 
reveals that increased frequency of additional steps during walking and shortened 
average stride length (Fig. 8D, E). Furthermore, the defect is not uni-lateral, as the 
mean stride length of left and right side is not significantly different (p = 0.786 by 
ANOVA) for both control and mutant mice. In summary, Pdss2
f/-
; Pcp2-cre mice 
develop a progressive ataxia phenotype comparable to human ubiquinone deficiency, 
as they become aged. 
(Video. 1-4) 
(Fig. 8) 
Progressive loss of cerebellum Purkinje cells and neuronal death by apoptosis may 
lead to the ataxia in aged Pdss2
f/-
; Pcp2-cre mouse 
 In mutant mice, Pcp2-cre drives Pdss2 knockout in Purkinje cells, whose defects 
are associated with cerebellar ataxia, so Purkinje cells are examined at different stages. 
At 1 month old, there is no obvious difference in the pattern or amount of Purkinje 
cells between control (Pdss2
f/+
; ROSA26
lacZ/+
; Pcp2-cre) and mutant (Pdss2
f/-
; 
ROSA26
lacZ/+
; Pcp2-cre) cerebellum, as shown by both X-gal staining and 
immunostaining for Purkinje cells (Fig. 9A-F). However, at 6 months old, the number 
of Purkinje cells has significantly decreased in the mutant cerebellum compared to 
that of control, as demonstrated by reduced blue signal of X-gal staining and very few 
cells positive for Purkinje cell marker (Fig. 9G-L). In consistent with the onset time of 
ataxia, increased apoptosis also starts at 6 months in the mutant cerebellum (Fig. 
10A-D), and more dispersed apoptosis can be detected at 9.5 months (Fig. 10E-H) by 
TUNEL assay. Similarly, electron microscopy also reveals apoptotic cells and swollen 
mitochondria in mutant mouse cerebellum at 8 months (Fig. 10I-L). Therefore, the 
gradual loss of Purkinje cells and initiation of diffusive neuron death by apoptosis 
may both contribute to atxia in aged Pdss2
f/-
; Pcp2-cre mice. 
(Fig. 9) 
(Fig. 10) 
  
Discussion 
 The Pdss2
f/-
; Pax2-cre mouse generated in this study not only reveals the 
important function of ubiquinone during mouse embryonic development but also 
recaptures some important features of human ubiquinone deficiency. Ubiquinone is 
known to play an essential role in mouse embryo development because complete 
knockout of Coq7, a gene involved in ubiquinone synthesis, results in embryo 
degeneration at E12.5 (Levavasseur et al., 2001). Similarly, the total knockout mouse 
(Pdss2
-/-
) we generated is also embryonic lethal around E9.5, and cerebellum 
hypoplasia is observed in all Pdss2
f/-
; Pax2-cre mice at birth, indicating a growth 
defect during embryonic development. In human, cerebellar atrophy is a common 
symptom of many subtypes of ubiquinone deficiency, and it may even appear at 
infantile stage (Lopez et al., 2006). Severe cerebellum hypoplasia in neonatal Pdss2
f/-
; 
Pax2-cre mice just recapitulates the similar feature in the human disease. Furthermore, 
abnormal lipid accumulation in skeletal muscle is another common symptom caused 
by ubiquinone deficiency, which may result from a defect in fatty acid metabolism. 
Because mitochondrial respiration is blocked due to ubiquinone deficiency, NADH 
generated by tricarboxylic acid (TCA) cycle cannot be converted to NAD
+
, which is 
an indispensible electron acceptor in lipid β-oxidation (Boitier et al., 1998; Ogasahara 
et al., 1989). In our case, excessive lipid accumulation is also found in limb muscles 
of newborn mutant mice. 
Recently, a similar Pdss2 conditional knockout mouse (Pdss2
loxp/loxp
) has been 
developed (Peng et al., 2008), in which Pdss2 exon 2 is also flanked by two LoxP 
sites. Before this mouse was reported, we had independently generated the Pdss2 
floxed mouse (Pdss2
f/f
) using a different targeting vector (see Supplementary data). 
When the Pdss2
loxp/loxp
 mouse is crossed to a podocyte specific deleter mouse 
(Podocin-cre), the resulting tissue specific knockout mouse develops a kidney disease 
comparable to that of kd/kd mouse, demonstrating that exon 2 is essential for PDSS2 
function. Furthermore, ubiquinone decrease is evident in specific tissues of the 
conditional knockout mouse (Peng et al., 2008), and kd/kd mouse has demonstrated 
improvement following oral CoQ10 treatment (Saiki et al., 2008). Thus, similar to the 
situation in human, the causative relation between defective PDSS2 protein and 
ubiquinone deficiency has been strongly implied in mouse. In our case, PDSS2 
protein is deficient in limb muscle and almost depleted in cerebellum of the Pdss2
f/-
; 
Pax2-cre mice, as shown by Western blot. Therefore, it is very likely that cerebellum 
hypoplasia observed in our mutant mice also results from PDSS2 based ubiquinone 
deficiency, although we cannot exclude the possibility that PDSS2 may have other 
unknown funtions during cerebellum development in addition to ubiquinone 
synthesis. 
 The pathogenesis of cerebellum hypoplasia has been studied during embryonic 
development for Pdss2
f/-
; Pax2-cre mice. Because the temporal and spatial control of 
Pdss2 knockout is achieved by Pax2-cre, a reporter (ROSA26
lacZ
) is introduced so that 
the regions of Pdss2 deletion can be revealed by β-galactosidase expression. Pax2 is 
initially expressed across isthmus at E8.0 in normal mouse embryo (Echevarria et al., 
2005), and β-galactosidase activity has become evident in the hindbrain region since 
E9.5 in Pax2-cre mouse (Ohyama and Groves, 2004). In Pdss2
f/-
; Pax2-cre mice, due 
to combined effect of cell proliferation and migration during cerebellum development, 
the actual region affected by Pdss2 knockout is further expanded to include most cells 
within cerebellum around the time of birth, which can be demonstrated by X-gal 
staining at E17.5. However, there is no apparent morphological difference between 
the cerebellar plate of control and mutant embryos before E11.5, and this can be 
accounted by a time lapse from the initiation of Pax2-cre expression to the onset of 
cellular defect due to Pdss2 knockout. E12.5-14.5 is a critical period of cerebellum 
development, and it is also the time when cerebellum growth retardation starts to 
appear in mutant embryos. One immediate cause of such defect is the failure in 
neuroblast radial migration and intermediate zone expansion, and delay or impairment 
of radial glial cell development seems to be a possible underlying reason. Interestingly, 
neither reduced cell proliferation nor ectopic apoptosis makes significant contribution 
to cerebellum growth retardation during this period, but they become the key factors 
leading to cerebellum hypoplasia after E14.5. Perhaps, ectopic apoptosis in the cells 
of intermediate zone is the most important factor, because impaired cell proliferation 
in the same region may also result from the loss of proliferating cells by apoptosis. As 
a result of extensive apoptosis of neurons in the intermediate zone, there are few cells 
left between the marginal zone and ventricular zone in mutant cerebellum at P0, and 
the normal cellular organization is also lost. In consistent with our results, apoptosis 
has been observed in skeletal muscles (Di Giovanni et al., 2001) and cultured skin 
fibroblasts (Rodriguez-Hernandez et al., 2009) from ubiquinone deficient patients. 
 Because of the important function of FGF8 in cerebellum and its close relation to 
Pax2 gene during early embryonic development, the effect of Pdss2 knockout on 
FGF8 production is also investigated for Pdss2
f/-
; Pax2-cre mice. Isthmus is an 
important secondary organizer at the junction between midbrain and hindbrain during 
early development. It emanates WNT1 to the anterior part (midbrain) and FGF8 to the 
posterior part (developing cerebellum and rhombomeres) from E9.5 to E12.5 (Joyner 
et al., 2000). FGF8 is a long-range diffusible growth factor that promotes cell 
proliferation and differentiation in the prospective cerebellum (Partanen, 2007). Thus, 
in Fgf8
f/-
; En1-cre conditional knockout mouse, the entire cerebellum is absent at 
E17.5 due to ectopic apoptosis since E9.0 (Chi et al., 2003). The establishment of 
isthmus organizer requires the participation of Otx2, Gbx2, Pax2, En1, and other 
genes expressed at the midbrain-hindbrain boundary. Pax2 is a prerequisite for the 
initial expression of Fgf8 at isthmus, whereas the proper gradient of OTX2 and GBX2 
maintains its stable expression (Ye et al., 2001). Therefore, defects of Pax2 also result 
in abnormal cerebellum development, as demonstrated by Pax2
1Neu
 mutant mouse, 
which shows cerebellum deletion at E14.5 owing to the loss of isthmus region at 
E12.5 (Favor et al., 1996). In the present study, Pdss2
f/-
; Pax2-cre mice also represent 
cerebellum hypoplasia due to ecotpic apoptosis, but the defect is less severe than 
those described above. As Cre recominase is induced by Pax2 expression, Pdss2 
knockout in the Pax2 positive cells at isthmus may influence later cerebellum 
development via reduced FGF8 production, even though there is no appearant 
abnormality before E11.5. However, in situ hybridization illustrates that Fgf8 
expression at isthmus is normal in the mutant mouse until E11.5. Therefore, the 
contribution of reduced FGF8 to cerebellum hypoplasia can be excluded. Perhaps, 
Pdss2 knockout has not caused substantial cellular defect to alter isthmic FGF8 
production before E12.5. 
 The Pdss2
f/-
; Pax2-cre mouse suffers from neonatal death, precluding further 
study at postnatal stages. Although cleft palate and micrognathia are considered as the 
main reasons, other factors may also contribute to the neonatal death. For example, 
renal failure may cause death in infants with ubiquinone deficiency (Lopez et al., 
2006), and Pax2-cre is also strongly expressed in kidney (Ohyama and Groves, 2004). 
Even though edema has not been observed in newborn mutant mice, the contribution 
of kidney disorder cannot be excluded. Besides, tongue plays an important role in the 
voluntary part of swallowing (McConnel et al., 1988), and its anterior portion also 
arises from the first branchial arch (the same origin as mandible), so defects in tongue 
muscle or innervation may cause dysphagia in the mutant mouse. Nevertheless, 
micrognathia and cleft palate are closely associated and often manifest simultaneously 
in Treacher Collins syndrome, Nager syndrome, or Pierre Robin sequence, and infants 
affected by those diseases also demonstrate dysphagia and respiratory distress 
(Posnick and Ruiz, 2000). Furthermore, microganthia and cleft palate can be caused 
by various genetic disorders, but they usually result from developmental defects in the 
first or second branchial arch (Marszalek et al., 2002). However, symptoms such as 
microganthia and cleft palate have not been reported in ubiquinone deficient patients. 
It has been demonstrated that the Pax2-cre mouse used in this study has an ectopic 
Cre expression in the first branchial arch at E9.5 (Ohyama and Groves, 2004), and 
β-galactosidase activity is also detectable in the same region at E10.5 by X-gal 
staining based on our results. Perhaps, unexpected Pdss2 knockout in the first 
branchial arch may result from this ectopic Pax2-cre expression. In addition, during 
E9.5-11.5, the migrating neural crest cells from hindbrain where Pax2-cre is 
expressed may also contribute to Pdss2 knockout in the first branchial arch. As a 
result, the development of mandible and maxilla is affected, leading to micrognathia 
and cleft palate in the mutant mouse. 
 In order to circumvent the problems caused by neonatal death in Pdss2
f/-
; 
Pax2-cre mice, we restricted the region and delayed the onset time of Pdss2 knockout 
by using a Pcp2-cre deleter mouse. In this new Pdss2 conditional knockout mouse 
(Pdss2
f/-
; Pcp2-cre), cre expression is confined to cerebellar Purkinje cells and only 
starts from P7 (Zhang et al., 2004), so characterization on adult mutant mice becomes 
possible. We chose this Pcp2-cre mouse also because Purkinje cells are the major 
inhibitory neurons in cerebellum and play an important role in motor coordination 
(Mauk, 1997). Consequently, lesions of Purkinje cells may cause cerebellar ataxia, 
which is also a hallmark of human ubiquinone deficiency in many adult patients 
(Lamperti et al., 2003). With the ROSA26
lacZ
 reporter, X-gal staining demonstrates 
that β-galactosidase has been expressed in most cerebellum Purkinje cells by 1 month 
(Fig. 9A, D), indicating Pdss2 knockout has already started at that time. Nevertheless, 
just as the situation in the cerebellum of Pdss2
f/-
; Pax2-cre mice before E12.5, the 
effect of Pdss2 knockout may be delayed since the Purkinje cells are still 
morphologically normal in 1 month old Pdss2
f/-
; Pcp2-cre mice. Similarly, the sign of 
cerebellar ataxia has not been observed even at 4.5 months. However, Purkinje cells 
are mostly depleted in the cerebellum of Pdss2
f/-
; Pcp2-cre mouse at 6 months (Fig. 
9G-L), and features of cerebellar ataxia also develops about 3 months later (Video 
3-4). By quantitative analysis of foot printing for aged mutant mice, impaired motor 
coordination is indicated by increased frequency of additional steps during walking, 
whereas shortened stride length reveals compromised ambulation capability. 
Therefore, unlike the Pdss2
f/-
; Pax2-cre mouse which demonstrates a developmental 
defect in cerebellum, the Pdss2
f/-
; Pcp2-cre mouse represents an example of neuron 
degeneration. More importantly, it recapitulates the progressive nature of ubiquinone 
deficiency and may serve as a better model for the ataxia form of human ubiquinone 
deficiency in adults. During the pathogenic course, Purkinje cell degeneration and 
subsequent diffusive neuron death by apoptosis may both contribute to the 
development of ataxia. Although Purkinje cells have been almost depleted in mutant 
cerebellum at 6 months, there has not been any significant ectopic apoptosis detected 
before that time. Furthermore, the pattern of apoptosis at later stages (6 months to 9.5 
months) does not entirely correlate to the normal anatomical location of Purkinje cells 
(Fig. 10D, H). As a result, Purkinje cell degeneration may not be attributed to ectopic 
apoptosis, and the late onset of diffusive apoptosis may reflect other neuron death 
secondary to Purkinje cell loss. The mechanism of Purkinje cell degeneration and 
rescue experiments using ubiquinone therapy in Pdss2
f/-
; Pcp2-cre mice will be of 
great interest in future study. 
Conclusions 
In conclusion, this study exploits the use of conditional knockout mouse to 
investigate the cerebellum defect of human ubiquinone deficiency. One tissue specific 
knockout mouse (Pdss2
f/-
; Pax2-cre) demonstrates cerebellum hypoplasia at birth, 
which resembles the cerebellum atrophy commonly observed in ubiquinone deficient 
infants. Moreover, by studying the pathogenesis of cerebellum hypoplasia during 
embryonic development, it reveals that Pdss2 knockout results in early cell migration 
defect, impaired cell proliferation, and increased ectopic apoptosis. Consistent with 
previous studies, mitochondrial defect may be the cause of apoptosis, and 
autophagic-like vacuolization may imply the involvement of mitophagy. The other 
tissue specific knockout mouse (Pdss2
f/-
; Pcp2-cre) demonstrates gradual loss of 
cerebellum Purkinje cells and develops cerebellar ataxia at old age, which 
recapitulates a more common ataxia form of ubiquinone deficiency in adults. To our 
knowledge, this is the first study that focuses on the cerebellum symptoms of 
ubiquinone deficiency using conditional knockout mouse models, and it also directly 
reflects the function of Pdss2 in cerebellar development. This study brings some 
insights into the pathogenesis of the cerebellar defect caused by ubiquinone 
deficiency. 
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Figure and video legeneds 
 
Fig. 1: Generation of Pdss2 conditional knockout mouse (Pdss2
f/-
; Pax2-cre). A: The 
structures of different Pdss2 alleles involved in the study are illustrated along with genotyping 
primers (upper panel). The sequences of those primers are given in Table 1. Typical PCR 
genotyping results are shown in the lower panel: Pdss2
f
 (584 bp) and Pdss2
+
 (422 bp) alleles 
were differentiated by CKO-f & CKO-r. Pdss2
-
 allele (522 bp) and Cre transgene (270 bp) 
were detected by KO-f & KO-r and Cre-f & Cre-r, respectively. These three sets of primers 
were used to identify the tissue specific knockout mouse. In this example, the four mice were 
genotyped as followed: 1 = Pdss2
f/-
; Pax2-cre, 2 = Pdss2
f/+
; Pax2-cre, 3 = Pdss2
f/+
, 4 = 
Pdss2
f/-
. Because genotyping for Cre is based on detecting Cre transgene without 
distinguishing Pax2-cre and Pcp2-cre, the same genotyping method also applies to another 
conditional knockout mouse (Pdss2
f/-
; Pcp2-cre). B: The cDNA structures (long isoform) of 
Pdss2
+
 and Pdss2
-
 are compared in the upper panel, and a representative RT-PCR result is 
shown below. By RT-f1 & RT-r5, there was a gap of 135 bp between Pdss2
+
 (798 bp) and 
Pdss2
-
 (663 bp) alleles due to the loss of exon 2. Sequencing of the two RT-PCR products by 
Pdss2-Ex3-seq-r further demonstrated that the 135 bp gap represents the deleted exon 2 in 
Pdss2
-
 mRNA (Supplementary data, Fig. S4). C: Western blot results comparing PDSS2 
protein in various tissues among Pdss2
f/+
 (C), Pdss2
f/-
 (H), Pdss2
f/-
; Pax2-cre (M) mice from 
the same litter. PDSS2 is detected at about 37 KDa, and α-tubulin at 55 KDa as an internal 
control. 
 
Fig. 2: Neonatal death and lipid accumulation in skeletal muscle. A-B: Whole mount skeleton 
preparation stained with Alcian blue & Alizarin red S (P0). In panel A, cleft palate is 
demonstrated by the yellow arrows in the ventral view of palate (mandible removed). 
Micrognathia is illustrated in panel B. The red arrow indicates that the shorter mandible fails 
to align with the maxilla in mutant mouse. Panels (A-B) are representative results of 5 control 
and mutant mice. C: Whole mount X-gal staining of Pax2-cre embryo at E10.5 (M: midbrain, 
H: hindbrain, FLB: forelimb bud). C’: A para-sagittal section through the first branchial arch 
(squared region in C), counter stained with nuclear fast red. Panels (C, C’) are representative 
images of 4 mice. D: Sudan black B staining counter stained by nuclear fast red (P0). The 
black dots represent lipid droplets in the mutant (Pdss2
f/-
; Pax2-cre). Panels in this figure are 
representatives of at least 3 mice in both control and mutant groups. Scale bars: 1.5 mm in (A); 
2 mm in (B); 1 mm in (C); 100 μm in (C') and (D). 
 
Fig. 3: Cerebellum hypoplasia around the time of birth. A-B: Coronal section of cerebellum 
at birth (H&E stain). Control: Pdss2
f/+
 (A), mutant: Pdss2
f/-
; Pax2-cre (B). A1-A2 and B1-B2 
are magnifications of the squared areas in A and B, respectively. Panels (A-B) are 
representatives of 4 control and 4 mutant mice. C-D: Immunostaining of Purkinje cells by 
anti-CALB-28K antibody at P0 (DAB counter stained with hematoxylin). Control: Pdss2
f/+
 
(C), mutant: Pdss2
f/-
; Pax2-cre (D). C’ is a magnification of the squared area in C, and the 
yellow arrows point to Purkinje cell clusters. Panels (C-D) are representatives of 3 control and 
3 mutant mice. E-G: Whole mount X-gal staining of mouse brain at E17.5. Only the midbrain 
and cerebellum are shown (dorsal view). Positive control: Pdss2
f/+
; ROSA26
lacZ/+
; Pax2-cre 
(E), mutant: Pdss2
f/-
; ROSA26
lacZ/+
; Pax2-cre (F), negative control: Pdss2
f/+
; Pax2-cre (G). 
The yellow arrow indicates severe hypoplasia of vermis in mutant cerebellum (F). H-I: 
Coronal section of stained cerebellum shown in E and F, counter stained by nuclear fast red. 
I’: A magnification of the squared area in I. Panels (E-I’) are representatives of 3 control and 
3 mutant mice. Scale bars: 300 μm in (A-B); 150 μm in (A1-A2), (B1-B2), (C), (H-I); 75 μm 
in (C'), (D), (I'); 1 mm in (E-G). 
 
Fig. 4: Cerebellum growth retardation from E12.5 to E14.5. A-B: Coronal section of 
cerebellum at E12.5 (H&E stain). Control: Pdss2
f/+ 
(A), mutant: Pdss2
f/-
; Pax2-cre (B). C-D: 
Coronal section of cerebellum at E14.5 (H&E stain). Control: Pdss2
f/+
 (C), mutant: Pdss2
f/-
; 
Pax2-cre (D). E-F: BrdU assay of cerebellum at E12.5 (DAB counterstained by hematoxylin). 
The red arrow indicates the cell layer above the proliferating (BrdU positive) cells. The 
yellow lines illustrate the columnar arrangement of cells and the trend of radial migration. 
Control: Pdss2
f/+
 (E), mutant: Pdss2
f/-
; Pax2-cre (F). G-H: BrdU assay of cerebellum at E14.5. 
Control: Pdss2
f/+
 (G), mutant: Pdss2
f/-
; Pax2-cre (H). Panels (A-H) are representative images 
of 4 control and 4 mutant mice at both E12.5 and E14.5. I-J: Immunostaing of nestin for 
radial glial cells at E12.5 (DAB). Control: Pdss2
f/+
 (I), mutant: Pdss2
f/-
; Pax2-cre (J). I’-J’: 
Magnifications of squared areas in I and J, respectively. The contour of mutant cerebellum is 
outlined by yellow dashed lines in J and J’. K-L: Immunostaining of Tuj1 (neuronal Class III 
β-tubulin) at E14.5 (DAB counter stained by hematoxylin). Control: Pdss2f/+ (K), mutant: 
Pdss2
f/-
; Pax2-cre (L). The red arrow indicates the thickness of Tuj1 negative cell layer. 
Panels (I-J’) are representatives of 3 control and 3 mutant mice. M: Overall cell density in the 
cerebellum of control (Pdss2
f/+
 or Pdss2
f/+
; Pax2-cre) and mutant (Pdss2
f/-
; Pax2-cre) 
embryos at E12.5 and E14.5. At E12.5, the overall cell density of control group (0.0258, ± 
0.00116 cells/μm2, n = 3) shows no significant difference from that of mutant group (0.0262, 
± 0.000823 cells/μm2, n = 4) by independent t test (p = 0.776, not labeled). Error bars 
represent ± SD (0.00202 for control and 0.00165 for mutant). At E14.5, the overall cell 
density of control group (0.0127, ± 0.000593 cells/μm2, n = 4) is significantly lower than that 
of mutant group (0.0200, ± 0.000868 cells/μm2, n = 4) by independent t test (p < 0.001). Error 
bars represent ± SD (0.00119 for control and 0.00174 for mutant). N: BrdU index in the 
cerebellum of control (Pdss2
f/+
 or Pdss2
f/+
; Pax2-cre) and mutant (Pdss2
f/-
; Pax2-cre) 
embryos at E12.5 and E14.5. At E12.5, the BrdU index of control group (23.09%, ± 0.00806, 
n = 3) has no significant difference from that of mutant group (20.37%, ± 0.0142, n = 4) by 
independent t test (p = 0.193, not labeled). Error bars represent ± SD (0.0140 for control and 
0.02840 for mutant). At E14.5, the BrdU index of control group (8.408%, ± 0.00436, n = 4) is 
very similar to that of mutant group (8.048%, ± 0.00594, n = 4) by independent t test (p = 
0.642, not labeled). The calculations for panels M-N are detailed in Materials and methods. 
Scale bars: 150 μm in (A-D) and (G-H); 75 μm in (E-F), (I-J), (K-L); 25 μm in (I'-J'). 
 
Fig. 5: The progression of cerebellum hypoplasia since E14.5. A-B: TUNEL assay of 
cerebellum coronal section at E14.5 (DAB counter stained by hematoxylin). Control: Pdss2
f/+
 
(A), mutant: Pdss2
f/-
; Pax2-cre (B). C: Percentage of apoptotic cells in total cells in the 
cerebellum of control (Pdss2
f/+
 or Pdss2
f/+
; Pax2-cre) and mutant (Pdss2
f/-
; Pax2-cre) 
embryos at E14.5. The percentage of apoptotic cells in mutant group (0.931%, ± 0.000311, n 
= 3) is significantly higher than that of control group (0.158%, ± 0.000242, n = 3) by 
independent t test (p < 0.001). Error bars represent ± SD (0.000538 for control and 0.000419 
for mutant). Calculation method is detailed in Materials and methods. D-E: TUNEL assay of 
cerebellum coronal section at E15.5 (DAB counter stained by hematoxylin). Control: Pdss2
f/+
 
(D), mutant: Pdss2
f/-
; Pax2-cre (E). F-G: TUNEL assay of cerebellum coronal section at 
E16.5 (DAB counter stained by hematoxylin). Control: Pdss2
f/+
 (F), mutant: Pdss2
f/-
; 
Pax2-cre (G). E’ and G’: Magnifications of squared areas in E and G, respectively. H-I: 
BrdU assay (DAB) on coronal sections of cerebellum pre-stained by whole mount X-gal 
staining at E17.5. Control: Pdss2
f/+
; ROSA26
lacZ/+
; Pax2-cre (H), mutant: Pdss2
f/-
; 
ROSA26
lacZ/+
; Pax2-cre (I). I’: A magnification of the squared area in I. J-K: TUNEL assay 
(FITC, green) co-stained for β-galactosidase (Cy3, red) on coronal cerebellum section at 
E18.5. Counter stained with DAPI (blue). Control: Pdss2
f/+
; ROSA26
lacz/+
 (J), mutant: Pdss2
f/-
; 
ROSA26
lacZ/+
; Pax2-cre (K). K’: A magnification of the squared area in K (the channel for 
DAPI is removed). The insert at the upper right is a close-up view of the squared area, and 
apoptotic bodies are indicated by yellow arrows. Scale bars: 150 μm in (A-B, D-E, F-G, H-I, 
J-K); 75 μm in (E'), (G'), (I'); 50 μm in (K').  
 
Fig. 6: Whole mount Fgf8 in situ hybridization (back view from the dorsal side). The yellow 
arrow in each panel indicates Fgf8 expression at isthmus. Scale bar: 0.2 mm. 
 
Fig. 7: Abnormal mitochondria and autophagic-like vacuoles in mutant cerebellum cells at 
E18.5. Coronal sections of cerebellum were examined by transmission electron microscopy. 
A: A normal cell in Pdss2
f/+
 (control) cerebellum (Nu: nucleus). B: Normal mitochondria (M, 
pointed by yellow arrows) in Pdss2
f/+
 cerebellum. C: An apoptotic cell in Pdss2
f/-
; Pax2-cre 
(mutant) cerebellum. D: Abnormal mitochondria (M*, pointed by yellow arrows) in Pdss2
f/-
; 
Pax2-cre cerebellum. Lys: lysosome. E-G: Autophagic-like structures in cells of Pdss2
f/-
; 
Pax2-cre cerebellum. A defective mitochondrion is engulfed by rER, indicated by yellow 
arrows (E). Residual bodies (R), indicated by yellow arrows (F). A magnification of the 
residual bodies (R) in a lysosome (Lys) (G). H: Comparison between the percentage of cells 
with autophagic-like morphology in Pdss2
f/+
 and Pdss2
f/-
; Pax2-cre cerebellum (4 randomly 
picked areas for each). Mean of control = 11.91% (SEM = 0.00874), mean of mutant = 30.90% 
(SEM = 0.00615). Error bars represent ± SD (0.0175 for control and 0.0123 for mutant). p < 
0.001 by independent t-test. Detailed calculation is given in Materials and methods. Scale 
bars: 2 μm in (A) and (C); 0.2 μm in (B) and (G); 0.5 μm in (D-F). 
Fig. 8: Foot print analysis of aged Pdss2
f/-
; Pcp2-cre mouse at 1 year old. A: A representative 
walking path of control mouse (Pdss2
f/+
; Pcp2-cre). B: An example of walking path of mutant 
mouse (Pdss2
f/-
; Pcp2-cre) with two additional steps indicated by gray arrow heads. C: An 
example of mutant foot print demonstrating that the mouse slides to the left during walking. 
The long gray arrow shows the direct of sliding between two adjacent steps. Panels A-C are 
representative pictures from 4 mutant mice (Pdss2
f/+
; Pcp2-cre) and 4 control littermates 
(Pdss2
f/-
; Pcp2-cre). D: Percentage of walking with additional steps. The mutant group 
(16.15%, ± 0.04288, n = 4) shows a significantly higher frequency of demonstrating 
additional steps during walking than the control group (8.576%, ± 0.06865, n = 4) by ANOVA 
(p = 0.018). The error bars represent ± SD (0.08576 for control and 0.13729 for mutant). E: 
Mean stride length. The measurements of stride length on the left and right side is pooled 
because side does not has a significant effect on the stride length (p = 0.786 by ANOVA). The 
mean stride length of mutant group (4.1, ± 0.2 cm, n = 4) is significantly shorter than that of 
control group (6.7, ± 0.3 cm, n =4) by ANOVA (p < 0.001). Detailed method of calculation is 
given in Materials and methods. 
Fig. 9: Progressive loss of cerebellum Purkinje cells in adult Pdss2
f/-
; Pcp2-cre mouse. A and 
D: Whole mount X-gal staining of cerebellum of Pdss2
f/+
; ROSA26
lacZ/+
; Pcp2-cre mouse (B) 
and Pdss2
f/-
; ROSA26
lacZ/+
; Pcp2-cre mouse (E) cerebellum at 1 month old. B-E: Para-sagittal 
section of X-gal stained cerebellum shown in A and D, respectively. C and F: 
Immunostaining of CALB-28K for Purkinje cells in Pdss2
f/+
; ROSA26
lacZ/+
; Pcp2-cre mouse 
(C) and Pdss2
f/-
; ROSA26
lacZ/+
; Pcp2-cre mouse (F) at 1 month old (para-sagittal section, 
DAB counterstained by hematoxylin). G and J: Whole mount X-gal staining of cerebellum of 
Pdss2
f/+
; ROSA26
lacZ/+
; Pcp2-cre mouse (G) and Pdss2
f/-
; ROSA26
lacZ/+
; Pcp2-cre mouse (J) 
cerebellum at 6 months. H and K: Para-sagittal section of X-gal stained cerebellum shown in 
G and J, respectively. I and L: Immunostaining of CALB-28K for Purkinje cells in Pdss2
f/+
; 
ROSA26
lacZ/+
; Pcp2-cre mouse (I) and Pdss2f/-; ROSA26lacZ/+; Pcp2-cre mouse (L) at 6 
months (para-sagittal section, DAB counterstained by hematoxylin). All panels are 
representatives of 3 mice. Scale bar: 1 mm in (A), (D), (G), and (J). 75 μm for all other 
panels. 
 
Fig. 10: Increased apoptosis in aged Pdss2
f/-
; Pcp2-cre mouse cerebellum. A-D: TUNEL 
assay (FITC) of Pdss2
f/+
 mouse cerebellum (A-B) and Pdss2
f/-
; Pcp2-cre mouse cerebellum 
(C-D) at 6 months. Nucleus counter stained with DAPI. E-H: TUNEL assay (FITC) of 
Pdss2
f/+ 
mouse cerebellum (A-B) and Pdss2
f/-
; Pcp2-cre mouse cerebellum (C-D) at 9.5 
months. Nucleus counter stained with DAPI. Panels (A-H) are representatives of 3 mice with 
the same genotype. I-L: Ultra-structure of Pdss2
f/+
 and Pdss2
f/-
; Pcp2-cre mouse cerebellum 
at 8 months. A representative apoptotic cell in mutant cerebellum (J) is compared with a 
normal cell in control cerebellum (I). Nu = nucleus. An example of swollen mitochondria in 
mutant cerebellum (L) is compared with normal mitochondria in control cerebellum (K). 
Scale bar: 150 μm in (A), (C), (E), (G); 75 μm in (B), (D), (F), (H); 2 μm in (I); 1 μm in (J); 
0.2 μm in (K); 0.5 μm in (L). 
 
Video. 1: Pdss2
f/+
; ROSA26
lacZ/+
; Pcp2-cre mouse at 4.5 months. The control mouse can walk 
normally on the bench and stand with its hind-limbs against the rim of the tray. 
 
Video. 2: Pdss2
f/-
; ROSA26
lacZ/+
; Pcp2-cre mouse at 4.5 months. The mutant mouse can also 
walk normally on the bench and stand with its hind-limbs against the rim of the tray as the 
control littermate shown in Video. 1. 
 
Video. 3: Pdss2
f/+
; ROSA26
lacZ/+
; Pcp2-cre mouse at 9.5 months. The control mouse can walk 
normally on the bench and is also capable of standing with its hind-limb against the rim of 
both low-edged plastic tray and high-edged paper box, just like those mice shown in Video. 1 
and 2. In addition, the mouse can maintain its balance and continuously walk on a rod. 
 
Video. 4: Pdss2
f/-;
 ROSA26
lacZ/+
; Pcp2-cre mouse at 9.5 months. The mutant mouse 
demonstrates defects in movement coordination when walking on the bench and fails to stand 
with its hind-limbs in either low-edged or high edged container. Furthermore, the mouse 
cannot maintain its balance on the rod. It frequently slips and eventually falls off. 
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 Table 1: Genotyping primers and amplification conditions 
Mouse Primers (5’-3’) PCR 
conditions 
Alleles Product 
(bp) 
Pdss2
f/+ CKO-f: 
TAGTCCTTTGTGAGTTACCCGTTGG 
Routine
a
, 
Ta 56℃ 
Pdss2
+ 422  
 CKO-r: 
GCCATTCACTTTCCACTGTCACC 
 Pdss2
f
 584  
Pdss2
+/-
 KO-f: 
GGGGAGTTATCATATCCGTTTATC 
Routine, 
Ta 58℃ 
Pdss2
+
 2,143  
 KO-r: 
GGGCAGGCTCAAAGTCAGGAAG 
 Pdss2
-
 522  
Pax2-cre Cre-f: 
GGACATGTTCAGGGATCGCCAGGCG 
Routine, 
Ta 58℃ 
Pax2-cre 270  
 Cre-r: 
GCATAACCAGTGAAACAGCATTGCTG 
   
ROSA26
lacZ/+ ROSA883(f): 
AAGTCGCTCTGAGTTGTTAT  
Routine, 
Ta 59℃ 
ROSA26
+ 550 
 ROSA2(r): 
GCGAAGAGTTTGTCCTCAACC 
ROSA3(r): 
GGAGCGGGAGAAATGGATATG 
Primer 
ratio
b
 
ROSA26
lacZ 300 
a: Routine PCR program: 95℃, 5 min. 95℃, 30 sec; Ta (as specified), 30 sec; 72℃, 45 sec, 
for 35 cycles. 72℃, 10 min. 
b: Primer ratio: three primers ROSA883:ROSA2:ROSA3 = 2:1:2 (molar ratio). 
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